357 related articles for article (PubMed ID: 18809602)
1. Adjuvant chemotherapy for non-small-cell lung cancer: a fading effect?
Besse B; Le Chevalier T
J Clin Oncol; 2008 Nov; 26(31):5014-7. PubMed ID: 18809602
[No Abstract] [Full Text] [Related]
2. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
[TBL] [Abstract][Full Text] [Related]
3. [Adjuvant chemotherapy in the early stages of non-small cell bronchial cancers].
Le Chevalier T
Rev Pneumol Clin; 2002 Nov; 58(5 Pt 2):3S31-2. PubMed ID: 12538932
[No Abstract] [Full Text] [Related]
4. Chemotherapy helps patients with advanced non-small cell carcinoma of the lung.
Socinski MA; Detterbeck FC; Rivera MP; Egan TM; Halle J; Rosenman J
N C Med J; 1996; 57(5):281-6. PubMed ID: 8854691
[No Abstract] [Full Text] [Related]
5. [Radio-chemotherapy combination in locally advanced, inoperable, non-small cell bronchial cancers].
Mornex F
Rev Pneumol Clin; 2002 Nov; 58(5 Pt 2):3S37-41. PubMed ID: 12538934
[No Abstract] [Full Text] [Related]
6. Mortality associated with pneumonectomy after induction chemoradiation versus chemotherapy alone in stage IIIA-N2 non-small cell lung cancer.
Van Schil PE
J Thorac Cardiovasc Surg; 2008 Mar; 135(3):718; author reply 718-9. PubMed ID: 18329516
[No Abstract] [Full Text] [Related]
7. Evaluation of the prognostic role of a panel of biomarkers in stage IB-IIIA non-small cell lung cancer patients.
Timotheadou E; Skarlos DV; Samantas E; Papadopoulos S; Murray S; Skrickova J; Christodoulou C; Papakostantinou C; Pectasides D; Papakostas P; Kaplanova J; Vrettou E; Karina M; Kosmidis P; Fountzilas G
Anticancer Res; 2007; 27(6C):4481-9. PubMed ID: 18214064
[TBL] [Abstract][Full Text] [Related]
8. [Chemotherapy in cancer of the lung].
Gütz S
MMW Fortschr Med; 2006 Jun; 148(22):33-4. PubMed ID: 16821578
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.
McKeage MJ; Reck M; Jameson MB; Rosenthal MA; Gibbs D; Mainwaring PN; Freitag L; Sullivan R; Von Pawel J
Lung Cancer; 2009 Aug; 65(2):192-7. PubMed ID: 19409645
[TBL] [Abstract][Full Text] [Related]
10. [Clinical advances in the chemotherapy of non-small cell lung cancer].
Liao ML; Cheng BJ
Zhonghua Jie He He Hu Xi Za Zhi; 2004 Jul; 27(7):480-2. PubMed ID: 15312563
[No Abstract] [Full Text] [Related]
11. [Therapeutic strategies in advanced non-small cell bronchial cancers: combinations without platin drugs].
Postmus P
Rev Pneumol Clin; 2002 Nov; 58(5 Pt 2):3S48-50. PubMed ID: 12538936
[No Abstract] [Full Text] [Related]
12. [Clinical investigation of weekly Carboplatin and Paclitaxel with concurrent radiation therapy for locally advanced non-small cell lung cancer].
Mito A; Yamasaki M; Matsuura K; Kajihara T; Nitta T; Awaya H; Arita K; Kashiwado K; Ohashi N
Gan To Kagaku Ryoho; 2009 Oct; 36(10):1653-6. PubMed ID: 19838022
[TBL] [Abstract][Full Text] [Related]
13. [Controversies in the treatment of non-small cell lung cancer; adjuvant chemotherapy].
Dediu M
Pneumologia; 2001; 50(2):115-7. PubMed ID: 11584671
[No Abstract] [Full Text] [Related]
14. [Taxol in bronchial carcinoma].
Gatzemeier U
Med Klin (Munich); 1996 Dec; 91 Suppl 2():1-6. PubMed ID: 9082171
[No Abstract] [Full Text] [Related]
15. Multicentre phase II trial of paclitaxel and carboplatin with concurrent radiotherapy in locally advanced non-small cell lung cancer.
Tell R; Sederholm C; Klintenberg C; Franksson L; Brandén E; Hillerdal G; Lönn U; Lindén CJ; Ewers SB; Lamberg K; Mrazek E; Lödén B; Sjögren A; Linné T; Friesland S; Sirzén F
Anticancer Res; 2008; 28(5B):2851-7. PubMed ID: 19031924
[TBL] [Abstract][Full Text] [Related]
16. Negative data from lung cancer trial may change practice guidelines, study designs.
McNeil C
J Natl Cancer Inst; 2006 Nov; 98(21):1518-20. PubMed ID: 17077353
[No Abstract] [Full Text] [Related]
17. Carboplatin-pemetrexed adjuvant chemotherapy in resected non-small cell lung cancer (NSCLC): a phase II study.
Karapanagiotou EM; Boura PG; Papamichalis G; Konstantinou M; Sepsas E; Chamalakis G; Simsiris P; Gkiozos I; Syrigos KN
Anticancer Res; 2009 Oct; 29(10):4297-301. PubMed ID: 19846990
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemotherapy for lung cancer.
Ikhlaque N; Baumann MA
N Engl J Med; 2004 Apr; 350(16):1681-3; author reply 1681-3. PubMed ID: 15084703
[No Abstract] [Full Text] [Related]
19. Re-evaluating duration of therapy in advanced non-small-cell lung cancer: is it really duration or is it more about timing and exposure?
Socinski MA
J Clin Oncol; 2009 Jul; 27(20):3268-70. PubMed ID: 19470913
[No Abstract] [Full Text] [Related]
20. Gender differences in treatment outcomes among patients with non-small cell lung cancer given a combination of carboplatin and paclitaxel.
Yamamoto H; Sekine I; Yamada K; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Tamura T
Oncology; 2008; 75(3-4):169-74. PubMed ID: 18827494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
